{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:24:16Z","timestamp":1772119456856,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00520-024-08480-9","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T23:41:11Z","timestamp":1712619671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of delayed pegfilgrastim administration following consolidation therapy with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) patients"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-1186","authenticated-orcid":false,"given":"Spencer K.","family":"Yingling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsea","family":"Seago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah Ud Din","family":"Safi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Cumpston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"1","key":"8480_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C (2016) An update of current treatments for adult acute myeloid leukemia. Blood 127(1):53\u201361. https:\/\/doi.org\/10.1182\/blood-2015-08-604520","journal-title":"Blood"},{"issue":"12","key":"8480_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"18","key":"8480_CR3","first-page":"4173","volume":"58","author":"CD Bloomfield","year":"1998","unstructured":"Bloomfield CD, Lawrence D, Byrd JC et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58(18):4173\u20134179","journal-title":"Cancer Res"},{"key":"8480_CR4","doi-asserted-by":"publisher","first-page":"32S","DOI":"10.1002\/j.1875-9114.1992.tb02680","volume":"12","author":"WP Petros","year":"1992","unstructured":"Petros WP (1992) Pharmacokinetics and administration of colony-stimulating factors. Pharmacotherapy 12:32S-38S. https:\/\/doi.org\/10.1002\/j.1875-9114.1992.tb02680","journal-title":"Pharmacotherapy"},{"key":"8480_CR5","unstructured":"Neulasta\u00ae OnPro\u00ae [package insert]. Thousand Oaks, CA: Amgen Inc; 2018"},{"issue":"8","key":"8480_CR6","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/annonc\/mdq674","volume":"22","author":"C Zwick","year":"2011","unstructured":"Zwick C, Hartmann F, Zeynalova S et al (2011) Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 22(8):1872\u20131877. https:\/\/doi.org\/10.1093\/annonc\/mdq674","journal-title":"Ann Oncol"},{"issue":"3","key":"8480_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1053\/j.seminhematol.2007.04.007","volume":"44","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Bug G, Krauter J (2007) Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. Semin Hematol 44(3):183\u2013192. https:\/\/doi.org\/10.1053\/j.seminhematol.2007.04.007","journal-title":"Semin Hematol"},{"issue":"6","key":"8480_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.leukres.2004.10.009","volume":"29","author":"A B\u00f6hm","year":"2005","unstructured":"B\u00f6hm A, Piribauer M, Wimazal F et al (2005) High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res. 29(6):609\u2013615. https:\/\/doi.org\/10.1016\/j.leukres.2004.10.009","journal-title":"Leuk Res."},{"issue":"5","key":"8480_CR9","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1038\/bcj.2017.45","volume":"7","author":"S Jaramillo","year":"2017","unstructured":"Jaramillo S, Benner A, Krauter J et al (2017) Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J 7(5):e564. https:\/\/doi.org\/10.1038\/bcj.2017.45","journal-title":"Blood Cancer J"},{"issue":"3","key":"8480_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00520-014-2417-7","volume":"23","author":"G Kam","year":"2015","unstructured":"Kam G, Yiu R, Loh Y et al (2015) Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. Support Care Cancer 23(3):643\u2013649. https:\/\/doi.org\/10.1007\/s00520-014-2417-7","journal-title":"Support Care Cancer"},{"key":"8480_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1471-2407-8-195","volume":"8","author":"J Sierra","year":"2008","unstructured":"Sierra J, Szer J, Kassis J et al (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 8:195. https:\/\/doi.org\/10.1186\/1471-2407-8-195","journal-title":"BMC Cancer"},{"issue":"4","key":"8480_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ajh.1052","volume":"66","author":"P van Der Auwera","year":"2001","unstructured":"van Der Auwera P, Platzer E, Xu ZX et al (2001) Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (ro 25\u20138315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol. 66(4):245\u2013251. https:\/\/doi.org\/10.1002\/ajh.1052","journal-title":"Am J Hematol."}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08480-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08480-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08480-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:11:48Z","timestamp":1715577108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08480-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["8480"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08480-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3293532\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board at WVU Hospitals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable\u2014research was retrospective in nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors grant final approval of the manuscript draft for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}